ArticleAmerican journal of translational research2026
Efficacy and safety of autologous hematopoietic stem cell transplantation for refractory systemic sclerosis after rituximab-bendamustine conditioning.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (auto-HSCT) using a novel rituximab-bendamustine conditioning regimen in patients with refractory systemic sclerosis (SSc).
methodsThis retrospective cohort study enrolled 216 patients with refractory SSc who received treatment between August 2019 and August 2023. Participants were divided into a transplant group (n=104) receiving the novel auto-HSCT regimen, and a conventional group (n=112) treated with prednisone combined with cyclophosphamide. Efficacy indicators, including the modified Rodnan skin score (mRSS), pulmonary, cardiac and renal function, organ involvement manifestations, autoantibody titers, quality of life (SF-36) scores, and clinical remission status, were assessed at baseline and 24 weeks post-treatment. Adverse events and progression-free survival (PFS) were also analyzed.
resultsAt the 24-week follow-up, the transplant group achieved significantly greater mRSS improvement (P<0.001). Significant improvements were also observed in pulmonary function (forced vital capacity [FVC], P=0.009) and cardiac function (left ventricular ejection fraction [LVEF], P=0.005) in the transplant group. The transplant group had a higher overall clinical remission rate (75.00% vs. 60.71%) and longer PFS (all P<0.05). Infusion reactions were more prevalent in the transplant group (15.38% vs. 4.46%), whereas gastrointestinal reactions and hyperglycemia occurred more frequently in the conventional group.
conclusionAuto-HSCT with a rituximab-bendamustine conditioning regimen yields superior improvements in multi-organ lesions and long-term survival outcomes in patients with refractory SSc compared with conventional therapy, with a tolerable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.